Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI ...

A compound designed to prevent chest pains in heart patients has shown promising results in animal studies, say scientists. In the second issue of the British Journal of Pharmacology to be published ...

DUBLIN--(BUSINESS WIRE)--The "Angina Pectoris: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering. This report focuses on the following forms ...

A new drug ranolazine is a safe and effective treatment for chronic stable angina and adds to the treatment options for patients with this condition. The treatment is discussed in a New Drug Class ...

CV Therapeutics Angina Drug Fails in New Heart Disease Test PALO ALTO, Calif., March 6 -- CV Therapeutics, Inc. announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ...

An angina drug called trimetazidine has been in the news lately connected to the 2022 Winter Olympics, but it's been on the radar of anti-doping authorities for years. Russian media reported that the ...

Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...

A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels - thereby reducing the risk of heart attack or stroke ...

BALTIMORE — The Food and Drug Administration has approved a generic heart disease drug made by Lupin, the Indian drug maker said. Lupin said the FDA approved its ranolazine extended-release tablets in ...

LOS ANGELES, March 27 (Reuters) - An angina drug made by CV Therapeutics Inc. failed to prove effective as a treatment for acute coronary syndrome, but favorable safety data could broaden its use, ...